Partnered Programs

Filter by:

  • Program
  • Preclinical
  • Clinical Candidate Pre-IND
  • IND-Enabling
  • Phase 1/2
  • Phase 3
  • Partner

Janssen

There are 500,000 influenza-related deaths annually worldwide. In addition to seasonal influenza, new strains of influenza have the potential to cause a global pandemic. Vaccines are not always effective at protecting humans from influenza, and may not be available during a pandemic. In collaboration with Janssen Pharmaceuticals, Inc., GTP is developing AAV-based prophylactics against influenza A and B as an alternative to the traditional influenza vaccine in the setting of seasonal and/or pandemic influenza infections.